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Summary
Idiopathic pulmonary fibrosis (IPF) is a chronic progress-
ive lung disease with poor survival. Recent studies have
improved understanding of IPF and new discoveries have
led to novel treatment options, which now have become
available for patients. In face of the newly available ther-
apies we present an update on the pathophysiology and epi-
demiology of IPF. We discuss the typical clinical findings
and elaborate diagnostic procedures according to current
guidelines and our daily practice approach. The role of bio-
markers will briefly be outlined. Finally, we discuss nov-
el antifibrotic treatment options for IPF (pirfenidone, nin-
tedanib) and the management of patients regarding to co-
morbidities and complications. Both pirfenidone and nin-
tedanib were shown to reduce the progression of IPF and
therefore represent novel therapeutic strategies in this so
far untreatable chronic lung disease.
Key words: idiopathic pulmonary fibrosis; idiopathic
interstitial pneumonia; nintedanib; pirfenidone
Introduction
Idiopathic pulmonary fibrosis (IPF) is a devastating, chron-
ic progressive lung disease with a median survival or time
to lung transplantation of about 3 years [1–3]. IPF mani-
fests predominantly in older males [4] and has been asso-
ciated with smoking [1, 5]. Radiological and pathological
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presentation is characterised by the typical usual interstitial
pneumonia (UIP) pattern (figs 1 and 2) [1]. The histopath-
ological hallmark of UIP is the heterogeneous distribution
and accumulation of myofibroblasts and extracellular mat-
rix in so-called fibroblast foci (fig. 2). The aetiology and
exact pathophysiological mechanism of the disease is still
unknown [1]. Until today no cure has been found. Lung
transplantation represents an option for selected patients
with advanced disease, with a median survival of approx-
imately 4.5 years after transplant [6]. Nevertheless, recent
studies improved our understanding of IPF and new dis-
coveries have led to novel treatment options, which now
have become available for patients. These treatment op-
tions slow down disease progression as documented by a
reduced decline in forced vital capacity (FVC). With re-
cent advances and future clinical trials, the fatal diagnosis
of IPF will hopefully be turned into a chronic, but treatable
disease. In face of the newly available therapies (perf-
enidone and nintedanib) we present an update on patho-
physiology, diagnosis and treatment of IPF.
Pathophysiology
Although the exact pathophysiological mechanism for IPF
is still not known in detail, intensive experimental and clin-
ical research efforts shed light on cellular and molecular
Figure 1
Chest computed tomography scan of a patient with idiopathic
pulmonary fibrosis. Typical radiological pattern of usual interstitial
pneumonia with traction bronchiectasis (arrow) and subpleural
honeycombing (star) is shown.
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mechanisms that seem to be essential for the development
of the disease. Previous views of inflammation as a central
force for fibrosis have been replaced by a concept of im-
paired alveolar wound healing (fig. 3a‒d) [7, 8]. Histolo-
gical studies not showing extensive signs of inflammation
in UIP and the failure of immunosuppressive therapies in
IPF supports rejection of the hypothesis of inflammation-
driven fibrosis in this disease [9]. Initial alveolar epithelial
type II cell damage by microinjuries and interruption of
the basal lamina in the alveoli is considered to be one
of the key trigger mechanisms (fig. 3b) [10]. Consecut-
ively released profibrotic factors lead to recruitment, pro-
liferation and differentiation of fibroblasts into myofibro-
blasts [11, 12], with the formation of typical fibroblast foci
(fig. 2) [1]. Production of extracellular matrix by myofibro-
blasts changes the alveolar architecture with thickening of
the air-blood barrier and consecutive impairment of blood
gas exchange and lung compliance. This results in hypox-
aemia on exertion and at later stages also at rest. Mul-
Figure 2
Histological usual interstitial pneumonia pattern: A typical fibroblast
focus is shown (arrow). (Haematoxylin and eosin staining;
magnification 200x.)
Figure 3
Hypothesis for pathophysiological mechanisms of idiopathic
pulmonary fibrosis development. Normal alveolar epithelium (fig.
3a) is injured by various mechanisms (fig. 3b). Alveolar epithelial
cells undergo apoptosis and the resulting gap is filled with a fibrin
clot (fig. 3c). Fibroblasts migrate in and proliferate (fig. 3c), and
differentiate into myofibroblasts. Extracellular matrix is produced
(fig. 3d) and accumulated fibroblasts further infiltrate the interstitium
leading to fibrosis.
tiple profibrotic pathways have been linked to pulmonary
fibrosis progression and are now target of new therapeut-
ic approaches reviewed recently [13]. Transforming growth
factor-beta (TGF-β) has been acknowledged as one of the
main profibrotic cytokines in IPF [14]. The inactive latent
form of TGF-β is activated in IPF via integrins, specific-
ally ανβ6. Active TGF-β mediates profibrotic effects, such
as epithelial cell apoptosis, epithelial-mesenchymal trans-
ition, extracellular matrix production and differentiation of
fibroblasts into myofibroblasts [14]. It also regulates in-
flammation and can suppress tumour growth. Inhibition of
TGF-β thus might lead to undesirable side effects and has
to be carefully controlled [14]. Currently, specific antibod-
ies against ανβ6 are being tested in IPF patients to prevent
activation from latent to active TGF-β, and other anti-TGF-
β targets are in development [15].
In addition to TGF-β, several profibrotic markers are re-
lated to IPF. We will briefly present a few of them relevant
for pharmacological inhibition by new therapeutic drugs.
Connective tissue growth factor (CTGF) is considered to
be a downstream mediator of TGF-β [14], and also of other
profibrotic mediators like thrombin [16]. CTGF has been
shown to be relevant in fibrosis development in various an-
imal models [17, 18], and has also been suggested to be a
biomarker for fibrosis in IPF [19]. Anti-CTGF antibodies
are currently being evaluated in clinical trials [15].
Platelet derived growth factor (PDGF) is another growth
factor involved in pulmonary fibrosis, mainly via chemo-
taxis induction and extracellular matrix stimulation of
(myo)fibroblasts [14]. Its antagonism has been tested as
therapeutic target in fibrotic disease and was reviewed re-
cently [20]. However, inhibition of PDGF signalling by
imatinib was not sufficient to slow down the progression of
IPF [21]. Vascular endothelial growth factor (VEGF) stim-
ulates (neo)angiogenesis and is increased in IPF patients
[22]. It is speculated that angiogenesis might be part of
fibrosis development or even of its endogenous resolution
strategy [23]. The potential of VEGF as a biomarker to pre-
dict disease course has been discussed [24]. In summary,
on the basis of previous studies, individual suppression of
growth factors, although crucial in the development of IPF,
may not be sufficient to inhibit the development of lung
fibrosis. However, an approach that simultaneously inhibits
several growth factors involved in the pathogenesis of IPF
may be more promising.
Lysophosphatidic acid (LPA) is a bioactive lipid mediator,
which is involved in different biological mechanisms, in-
cluding development (brain) and pathophysiological con-
ditions like neuropathic pain, and renal and pulmonary
fibrosis [25]. Among other functions, it is chemoattractant
for fibroblasts and contributes to fibrosis [26]. It induces
epithelial cell apoptosis and promotes fibroblast survival,
which are essential hallmarks in the pathogenesis of pul-
monary fibrosis [27]. In IPF patients, LPA levels are elev-
ated in bronchoalveolar lavage (BAL) and exhaled breath
condensate [26, 28]. Pharmaceutical antagonism of fibrosis
is currently being addressed in IPF in a phase II clinical tri-
al [15, 29].
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Epidemiology, genetics, risk factors
IPF is more frequently observed in males than females and
gender influences survival prediction in currently proposed
staging systems [3, 4]. The disease is mainly diagnosed
after 50 years of age [1]. As our population is increasingly
aging, we will expect higher prevalence and incidence of
IPF in the near future.
The prevalence and incidence of IPF varies depending on
the country and case definition [30], which changed over
the last decade. The annual prevalence in the United States
was estimated as 14.9 to 27.9 or 42.7 to 63 per 100,000
population (depending on the respective case defini-
tions).[30]. Based on recent data, the prevalence of IPF was
1.25 to 23.4 per 100,000 population in European studies
in Belgium, the Czech Republic, Finland, Greece, Italy or
Norway, or multinational studies [30]. In one study, preval-
ence in patients over 75 years reached more than 170 per
100,000 [4]. The annual incidence in the US was estimated
to be 6.8 to 8.8 or 16.3 to 17.4 per 100,000 population (de-
pending on the respective case definitions) [30]. In Europe
the incidence is reported to be between 0.22 to 7.94 per
100,000 [30]. No data are available for Switzerland so far.
With a current population of approximately 8 million in-
habitants [31], the number of patients in Switzerland might
vary from 100 to over 5,000 patients (prevalence 1.25–63
cases/100,000) and the annual incidence between 18 and
1,424 patients/year (0.22–17.4 cases/100,000). The differ-
ences in prevalence and incidence in available data points
to difficulties of data collection between individual nation-
al registers, and highlights the importance of globally struc-
tured registers, especially for rare diseases such as IPF [32].
IPF is found in familial clusters [33] as well as sporadic
forms. Genetic mutations have been observed in both set-
tings [34, 35]. In sporadic IPF, the following mutations
were observed: MUC5B (35%), SPC (1%), SPA (1%),
TERT and TERC (3%) [35].
Gastro-oesophageal reflux is common in patients with IPF
[36]. However, whether gastro-oesophageal reflux repres-
ents a risk factor for IPF remains unclear [37]. Smoking has
been associated with IPF and is considered a risk factor [1,
38]. Environmental factors are also thought to play a role
in the development of IPF [1]. With adjusted for age and
smoking, dusty environments were associated with a high-
er risk for developing IPF [39]. The dusts included were
specifically metal dust, and farming, livestock, hairdress-
ing, raising birds, stone cutting, vegetable and animal dust
[39].
Although viral infection (e.g. herpes and other viruses such
as hepatitis C and B, Epstein Barr virus etc. [40]) has been
suggested to contribute to the progression in IPF [1, 41],
current literature suggests a possible role for bacteria and
change in microbiome in IPF development [40, 42]. Spe-
cific bacteria of the lung microbiome from IPF patients are
associated with disease progression [43]. However, if al-
terations in lung microbiome are cause or consequence of
fibrosis still needs to be addressed.
Clinical presentation, diagnosis,
classification
Clinical symptoms are nonspecific and consist of exercise-
induced dyspnoea and dry cough. Progressive fibrotic re-
placement of the normal lung architecture impairs gas ex-
change and goes along with a restrictive ventilatory defect.
Lung auscultation reveals characteristic bilateral inspirat-
ory crackles at the lung bases.
Since evidence of possible aetiologies of the fibrotic lung
disease is not a prerequisite for diagnosis of IPF, an ex-
tensive patient history is crucial. In particular, we check for
environmental and occupational exposures to particulates,
collagen-vascular diseases (e.g. systemic sclerosis, rheum-
atoid arthritis), intake of lung-toxic medications, family
history, and potential disease-triggering comorbidities,
such as gastro-oesophageal reflux symptoms. IPF patients
often present with asymptomatic reflux and microaspira-
tion, which are difficult to diagnose [44]. In absence of a
current agreement, we do not routinely perform 24-hour pH
monitoring, only if atypical symptoms are present.
We additionally search for comorbidities such as obstruct-
ive sleep apnoea syndrome (OSAS), pulmonary hyperten-
sion and lung cancer. OSAS has a high prevalence in IPF
patients [45]. Nocturnal respiratory polygraphy is per-
formed if the patient is symptomatic (increased daytime
sleepiness). Pulmonary hypertension should be searched
for with echocardiography, especially if reduction in diffu-
sion capacity and/or hypoxaemia is discordant with fibrot-
ic changes, as we might consider treatment in patients with
Figure 4
Diagnostic algorithm for suspected idiopathic pulmonary fibrosis. In
the case of suspicion the patient is evaluated by an experienced
pulmonologist. High-resolution computed tomography and
bronchoalveolar lavage are performed. If the diagnosis is not clear
the patients are discussed at a multidisciplinary interstitial lung
disease (ILD) board and further diagnostic steps are taken if
indicated (modified from [1].
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pulmonary-arterial hypertension (group 1) according to
current recommendations. Vasoactive treatment is actually
not recommended in patients with pulmonary hypertension
related to lung disease (group 3) and might even be harmful
as a result of a worsened ventilation/perfusion ratio and,
therefore, impaired gas exchange under treatment in these
patients [46]. Coronary artery disease and pulmonary em-
bolism should be sought if suspected [1]. IPF is associated
with an increased risk of lung cancer, and influences sur-
vival after surgery [47]. Reported cancer types are squam-
ous cell carcinoma and adenocarcinoma, but other histo-
logical types can also occur [47]. Computed tomography
(CT) scans should be monitored carefully for suspicion le-
sions, however regular CT screening for cancer is not re-
commended in IPF patients
Laboratory work-up for IPF patients should include blood
sedimentation rate, haematological blood differentiation,
C-reactive protein, renal and hepatological parameters. We
routinely determine serological markers for systemic
rheumatic diseases (e.g. antinuclear antibodies, antineutro-
phil cytoplasmic antibodies, rheumatic factor, anti-cyclic
citrullinated peptide [CCP]) to rule out pulmonary mani-
festations of a so-far undetected rheumatic disease. General
serological screening for rheumatic diseases in ILD may be
reasonable since fibrotic lung disease may be present long
before rheumatic symptoms. Specific markers are only
measured in the case of clinical suspicion (i.e. anti-Jo,
SS-A, SS-B, anti-centromeres, anti-topoisomerase, anti-
U3–RNA).
For diagnosis of IPF, high-resolution computed tomo-
graphy (HRCT) of the lung is essential. Radiological criter-
ia for IPF are classified into three categories: UIP pattern,
possible UIP and inconsistent with UIP pattern [1]. The
diagnosis of a UIP pattern requires subpleural and basal
predominance, reticular abnormalities, honeycombing with
or without traction bronchiectasis (example see fig. 1) and
absence of features inconsistent with UIP pattern, such as
upper or mid-lung predominance, peribronchovascular pre-
dominance, extensive ground glass shadowing, profuse mi-
cronodules, discrete cysts, diffuse mosaic attenuation or
air trapping, and consolidation in bronchopulmonary seg-
ments or lobes [1]. In addition to HRCT, we perform bron-
choscopy and BAL if possible, as lymphocytosis >15% or
eosinophilia >1% favours an alternative diagnosis to IPF
[48, 49]. In specific cases, transbronchial biopsies and/or
cryobiopsies are taken, in particular to rule out differential
diagnoses such as sarcoidosis or lymphangiosis carcino-
matosa.
Interstitial lung diseases (ILDs) are classified into ILD sec-
ondary to an identified cause or of idiopathic origin, called
idiopathic interstitial pneumonia (IIP). IPF is considered
one of the major IIPs. A recent summary of the new clas-
sification gives an overview of the differential diagnosis
for IPF [50]. The main emphasis for IPF diagnosis and
the gold standard are now laid on multidisciplinary board
discussions to improve diagnostic accuracy [1, 51]. These
multidisciplinary boards should include a pulmonologist,
a radiologist and a pathologist [50]. In a study evaluating
the impact of multidisciplinary boards, clinicians identified
the diagnosis in 75% and radiologists in 48% of cases be-
fore presentation of the histopathological information [51].
The radiologist changed diagnosis after histopathological
information to a greater extent than did clinicians [51]. This
study illustrates an important challenge in IPF diagnosis:
the radiological UIP pattern alone in the correct clinical
context is sufficient for the diagnosis of IPF [1], but dia-
gnosis of IPF by a radiologist alone is not accurate, since
the differential diagnoses need to be ruled out when a radi-
ological UIP pattern is present. Diagnosis and working out
the differential diagnosis for IPF is crucial and can be chal-
lenging. Referral to a specialised ILD centre allows the ac-
cess to multidisciplinary boards and, if possible, inclusion
in clinical trials or registries. Moreover, interdisciplinary
boards that are open to all treating physicians, both in hos-
pital and out of hospital based, allow optimal patient care
by coordination between specialised ILD centres, the treat-
ing pulmonologists as well as primary care physicians. A
specialised nurse for ILD patients may further support op-
timal care in patient-related issues (e.g. medication, long-
term oxygen therapy, pulmonary rehabilitation, psychoso-
cial support).
A diagnostic algorithm for suspected IPF is presented in
figure 4.
Course of disease, biomarkers for
disease monitoring
IPF can have various disease courses [1]. Whereas some
patients remain almost stable over years, some experience
rapid progression. Another group presents with repetitive
acute worsening that can be secondary to pulmonary em-
bolism, pneumothorax, infection or heart failure. If no
cause can be identified the term acute exacerbation is used
[1, 52]. Acute exacerbations in IPF are defined in the cur-
rent guidelines as an unexplained worsening of dyspnoea
within 1 month, evidence of hypoxaemia as defined by
worsened or severely impaired gas exchange, new radio-
graphic alveolar infiltrates and an absence of an alternative
explanation (infection, pulmonary embolism, pneumothor-
ax or heart failure) [1]. Probably many acute exacerbations
in IPF have some underlying unrecognised trigger and the
requirement of idiopathic genesis of acute exacerbations is
currently challenged [53]. This is why clinical treatment in-
cludes empirical antibiotic treatment even if no pathogen
has been identified [54]. Unfortunately, the clinical course
of IPF is unpredictable at diagnosis.
New therapeutic options for IPF
Due to novel insights and treatment possibilities in IPF the
international guidelines published in 2011 [1] do not reflect
the current standard of treatment. Meanwhile, national up-
dates have been published in Europe [55–57].
Over the last decades many therapeutic concepts proved
to be unsuccessful. In particular, immunosuppressive treat-
ment did not show any benefit [9]. In this respect, treatment
with corticosteroid monotherapy, colchicine, ciclosporin,
corticosteroid and immunomodulation (azathioprine [9],
cyclophosphamide, etanercept), N-acetylcyteine [58],
Interferon-γ1b [59], bosentan [60] or ambrisentan [61] or
imatinib [21] did not show to be of sufficient benefit and
were therefore disapproved in recent guidelines [1].
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In particular, a placebo-controlled randomised trial had to
be stopped early over safety concerns in the arm treated
with prednisone, azathioprine and N-acetylcysteine
(PANTHER-IPF study) [9]. Immunsuppression should thus
not be used in IPF. The placebo arm and the N-acetyl-
cysteine arm of the PANTHER-IPF study were continued
to evaluate the effect of N-acetylcysteine alone on IPF
[58]. After 60 weeks no difference in FVC was observed
between N-acetylcysteine and placebo [58]. Although an
initial small study showed a survival benefit in IPF patients
under anticoagulation therapy during acute exacerba-
tion,[62] a larger study showed increased mortality with
long term warfarin therapy in IPF [63]. Anticoagulation
should thus not be used in IPF.
After years of disappointing clinical trials in IPF, there is
now light on the horizon regarding treatment of IPF since
two agents, pirfenidone and nintedanib, showed positive
effects on slowing the progression of the disease and are
now available for IPF patients in Switzerland via specific
compassionate use program.
Pirfenidone
Pirfenidone is a new oral antifibrotic agent that inhibits
the TGF-β pathway. The exact cellular mechanisms of ac-
tion are unknown. Two out of three previously conducted
phase III trials with pirfenidone showed reduced disease
progression, measured as forced vital capacity (FVC) or vi-
tal capacity in patients with IPF [64, 65]. Last year a fourth
phase III trial was published, which showed reduced dis-
ease progression in lung function, exercise tolerance and
progression-free survival compared with placebo in a total
of 555 patients over 52 weeks [66]. The primary endpoint,
reduction in FVC, showed a mean difference in decline of
193 ml between the placebo and treatment groups (235 ml
mean decline from baseline in pirfenidone group, 428 ml
mean decline from baseline in placebo group). Moreover,
the pirfenidone group showed a nonsignificant trend to
reduced mortality. Although objective differences in this
study were convincing, no difference in perception of dys-
pnoea could be found [66]. Cough seemed to be reduced
in the pirfenidone treated group but has not been analysed
objectively. Side effects included gastrointestinal disturb-
ances and phototoxicity, which required specific protective
measures such as sun protective clothing and sun screen.
In daily practice gastrointestinal and phototoxic side effects
can often be managed by temporary dose reduction (inten-
ded dose 3 x 3 cps of 267 mg pirfenidone per day) and
intake of pirfenidone during meals. In our experience dis-
continuation of the drug is rarely necessary although real
life experiences from other centres reported discontinu-
ation rates up to 20% due to side effects [67]. While pirf-
enidone has already been approved in Europe [68], Japan,
Canada and the USA [69], official approval in Switzerland
is pending. However, pirfenidone can be prescribed by ILD
specialised centres.
Nintedanib
Nintedanib is an intracellular inhibitor of several tyrosine
kinases, inhibiting PDGF, VEGF and FGF. Two phase III
trials of nintedanib evaluated the efficacy and safety of nin-
tedanib in a total of 1,066 patients over 52 weeks. nintedan-
ib reduced the decline of FVC (100 ml FVC decline in nin-
tedanib treated group vs 220 ml decline in placebo group).
It also reduced the occurrence of acute exacerbations. No
difference was observed with regard to diffusion capacity
for CO (DLCO) measurement or in 6-minute walking dis-
tance. Side effects frequently included diarrhoea; however,
discontinuation of the drug was only necessary in fewer
than 5% of patients [70]. Side effects can generally be man-
aged using antidiarrhoeal medication and/or dose reduction
(intended dose 2 x 150 mg nintedanib, reduction to 2 x 100
mg possible). Nintedanib is not approved in Switzerland
yet, but has been available through a compassionate use
programme in ILD specialised centres since 2014.
Use of antifibrotic agents
Based on the study selection criteria of the respective trials,
treatment with pirfenidone is effective with a FVC of
50%–90%, DLCO 30%–90%, FEV1/FVC >0.80 and a
6-minute walking distance of >150 m [66]. Nintedanib
was shown to be effective in patients with FVC >50%,
DLCO 30%–79% and FEV1/FVC >0.70 [70]. It is prob-
able, but unproven, that more severe forms might also be-
nefit from antifibrotic treatment if side effects are tolerable.
Lung transplantation remains the last option. Whether anti-
fibrotics should be discontinued before lung transplantation
(possibility of impaired wound healing) should be evalu-
ated with the respective transplantation centre.
Antifibrotic treatment should be started in symptomatic pa-
tients with loss of FVC. However, based on the present
knowledge it is not clear if antifibrotic treatment should be
started in clinically stable patients with mild IPF. In stable
and/or unimpaired patients treatment introduction might
be evaluated according to lung functional decline over 3
months. Alternatively, an immediate start should always be
discussed with the patient, as lost lung function will not re-
cover under treatment.
With currently available data no superiority of either med-
ication can be concluded from the published studies.
Choice of antifibrotics should be based on comorbidities,
potential side effects considering life style (phototoxicity)
and also patients’ preferences. Head to head comparisons
will be needed to determine equal efficacy of both treat-
ments.
The combination of pirfenidone and nintedanib has been
evaluated with regards to safety and pharmacokinetics,
with lower levels of nintedanib when added to pirfenidone
[71]. A synergistic effect on outcome has not been studied
in a clinical trial so far.
Pulmonary rehabilitation
Although there are only few studies investigating the ef-
fects of pulmonary rehabilitation in IPF patients [72], pul-
monary rehabilitation seems to be beneficial regarding ex-
ercise capacity and quality of life [73]. Short-term treat-
ment efficacy for clinical improvement has been proven in
a recent study with IPF patients [74]. Pulmonary rehabilit-
ation should thus be offered to patients with IPF, in either
the out- or inpatient setting.
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Long-term oxygen therapy
Hypoxia at rest and even more during exercise is common
in patients with ILD. Long-term-oxygen therapy in hypoxic
patients with IPF has not been appropriately studied until
today regarding its prognostic benefit in ILD. Retrospect-
ive studies suggest a benefit in exercise performance with
appropriate flow rates [75]. High oxygen supply and mo-
bility can be guaranteed using liquid oxygen as well as
controlled oxygen release upon inspiration. The exact oxy-
gen need should always be titrated at rest, during night
as well and in particular during exercise. We usually per-
form a 6-minute walking test to titrate the optimal oxygen
dose under exercise, aiming at a minimal oxygen saturation
level of 90% under exercise. Despite the lack of properly
designed studies, supplemental oxygen reduces symptoms,
specifically dyspnoea on exertion. Therefore, oxygen sup-
plementation is currently recommended in international
guidelines [1].
Mechanical ventilation
Mechanical ventilation in IPF patients with respiratory fail-
ure should be reserved to a minority. Invasive ventilation
in IPF patients admitted to the intensive care unit was as-
sociated with a high mortality [76]. Invasive mechanical
ventilation should be considered only if used as bridge for
preplanned lung transplantation. Although large prospect-
ive studies are not available, non-invasive ventilation has
been suggested for acute exacerbation and acute respiratory
failure in IPF patients [77, 78].
Lung transplantation
IPF accounts for the largest patient group on the transplant
list and survival post-transplant is estimated as 4.5 years
[6]. With 5-year survival rates of about 50% internationally
[6], and even higher in Switzerland [79], and evidence of
favourable long-term survival in IPF patients after lung
transplantation, current statements recommend early eval-
uation for lung transplantation of patients with progressive
IPF disease with limited diffusion capacity [1].
Treatment of comorbidities and
complications
Acute exacerbation of IPF
The initial steps in face of a patient with clinical worsening
is the exclusion of treatable causes such as pulmonary
infection, lung embolism, pneumothorax, cardiac decom-
pensation, or stenosing lung cancer. If no treatable cause
can be identified, the clinical worsening is assumed to be
due to an acute exacerbation of the disease. Although high-
dose steroid treatment is recommended for acute exacerba-
tions in IPF [1], evidence for efficacy is lacking and pro-
spective clinical trials are needed to determine its role [80].
If the clinical situation allows a bronchoscopy, BAL should
be performed to rule out pulmonary infection before start-
ing steroid therapy. Antibiotic treatment depends on the
clinical situation and/or the BAL results. Mechanical vent-
ilation may be needed although it needs to be taken into
consideration that the weaning process may be challenging.
Treatment of pulmonary hypertension
Pulmonary hypertension occurs in more than 45% of pa-
tients suffering from IPF and awaiting lung transplantation
[81]. Currently there is no general recommendation for the
treatment of pulmonary hypertension in IPF patients [1].
Various treatments have been tested, but failed to show im-
proved outcome [82]. Additional prospective studies are
needed to determine the role of specific vasoactive treat-
ment of pulmonary hypertension in IPF.
Gastro-oesophageal reflux treatment
Gastro-oesophageal reflux has been associated with the
development of IPF, and reflux therapy is estimated to
be beneficial in symptomatic and asymptomatic IPF pa-
tients, although controlled clinical trials are needed [83].
At this time, although current guidelines recommend that
both symptomatic and asymptomatic gastro-oesophageal
reflux should be treated in patients with IPF [1], there is
consensus only that symptomatic IPF patients should be
treated with PPI. In asymptomatic patients, treatment indic-
ation remains controversial and additional studies need to
be performed.
Palliative care
Although palliative care is a major aspect for a devastating
disease like IPF, recent international statements did not
give detailed recommendations [1]. A nurse specialised for
ILD can be very supportive for IPF patients in several as-
pects including medical treatment, long-term oxygen treat-
ment, and also economical aspects (healthcare). At what
time point antifibrotic therapy should be stopped, is un-
defined. Definitively, medication should be stopped once
the palliative stage is entered to avoid unnecessary side ef-
fects.
Dyspnoea and cough are the main symptoms in progressive
disease, reduce quality of life and are difficult to treat. Pirf-
enidone might have some effects on cough [84], and is cur-
rently studied. Specifically, cough in IPF is often resistant
to anticough medications and novel therapeutic approaches
are definitively needed.
Outlook
Treatment of IPF shows a turning point now as two new
antifibrotic agents are available which have shown reduc-
tion in disease progression in placebo-controlled trials. Al-
though disease improvement or even cure can still not be
expected, there is hope that future drugs and combination
therapies are able to transform IPF from a lethal to a chron-
ic, but treatable, disease. It is of utmost importance to de-
termine prevalence and incidence in Switzerland to optim-
ise accessibility of new treatments for these patients. A
national register will be set up and help to structure and
control quality of care for IPF patients. National and in-
ternational collaborations are crucial to get more insight in
IPF and its novel therapies. Collaboration with specialised
ILD centres should be achieved for accurate diagnosis and
treatment, to collect clinical data in patient registries and
include patients in clinical trials, whenever possible.
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Figures (large format)
Figure 1
Chest computed tomography scan of a patient with idiopathic pulmonary fibrosis. Typical radiological pattern of usual interstitial pneumonia with
traction bronchiectasis (arrow) and subpleural honeycombing (star) is shown.
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Figure 2
Histological usual interstitial pneumonia pattern: A typical fibroblast focus is shown (arrow). (Haematoxylin and eosin staining; magnification
200x.)
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Figure 3
Hypothesis for pathophysiological mechanisms of idiopathic pulmonary fibrosis development. Normal alveolar epithelium (fig. 3a) is injured by
various mechanisms (fig. 3b). Alveolar epithelial cells undergo apoptosis and the resulting gap is filled with a fibrin clot (fig. 3c). Fibroblasts
migrate in and proliferate (fig. 3c), and differentiate into myofibroblasts. Extracellular matrix is produced (fig. 3d) and accumulated fibroblasts
further infiltrate the interstitium leading to fibrosis.
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Figure 4
Diagnostic algorithm for suspected idiopathic pulmonary fibrosis. In the case of suspicion the patient is evaluated by an experienced
pulmonologist. High-resolution computed tomography and bronchoalveolar lavage are performed. If the diagnosis is not clear the patients are
discussed at a multidisciplinary interstitial lung disease (ILD) board and further diagnostic steps are taken if indicated (modified from [1]).
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